185 related articles for article (PubMed ID: 19506354)
1. C1584: effect on von Willebrand factor proteolysis and von Willebrand factor antigen levels.
Davies JA; Collins PW; Hathaway LS; Bowen DJ
Acta Haematol; 2009; 121(2-3):98-101. PubMed ID: 19506354
[TBL] [Abstract][Full Text] [Related]
2. Laboratory diagnosis and molecular basis of mild von Willebrand disease type 1.
Michiels JJ; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van Vliet HH
Acta Haematol; 2009; 121(2-3):85-97. PubMed ID: 19506353
[TBL] [Abstract][Full Text] [Related]
3. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
[TBL] [Abstract][Full Text] [Related]
4. C1584 in von Willebrand factor is necessary for enhanced proteolysis by ADAMTS13 in vitro.
Keeney S; Grundy P; Collins PW; Bowen DJ
Haemophilia; 2007 Jul; 13(4):405-8. PubMed ID: 17610557
[TBL] [Abstract][Full Text] [Related]
5. The prevalence of the cysteine1584 variant of von Willebrand factor is increased in type 1 von Willebrand disease: co-segregation with increased susceptibility to ADAMTS13 proteolysis but not clinical phenotype.
Bowen DJ; Collins PW; Lester W; Cumming AM; Keeney S; Grundy P; Enayat SM; Bolton-Maggs PH; Keeling DM; Khair K; Tait RC; Wilde JT; Pasi KJ; Hill FG;
Br J Haematol; 2005 Mar; 128(6):830-6. PubMed ID: 15755288
[TBL] [Abstract][Full Text] [Related]
6. Effect of von Willebrand factor Y/C1584 on in vivo protein level and function and interaction with ABO blood group.
Davies JA; Collins PW; Hathaway LS; Bowen DJ
Blood; 2007 Apr; 109(7):2840-6. PubMed ID: 17119126
[TBL] [Abstract][Full Text] [Related]
7. Dominant von Willebrand disease type 2A groups I and II due to missense mutations in the A2 domain of the von Willebrand factor gene: diagnosis and management.
Michiels JJ; van Vliet HH
Acta Haematol; 2009; 121(2-3):154-66. PubMed ID: 19506362
[TBL] [Abstract][Full Text] [Related]
8. Characterization of recessive severe type 1 and 3 von Willebrand Disease (VWD), asymptomatic heterozygous carriers versus bloodgroup O-related von Willebrand factor deficiency, and dominant type 1 VWD.
Michiels JJ; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van de Velde A; van Vliet H
Clin Appl Thromb Hemost; 2006 Jul; 12(3):277-95. PubMed ID: 16959681
[TBL] [Abstract][Full Text] [Related]
9. von Willebrand factor: evidence for variable clearance in vivo according to Y/C1584 phenotype and ABO blood group.
Davies JA; Collins PW; Hathaway LS; Bowen DJ
J Thromb Haemost; 2008 Jan; 6(1):97-103. PubMed ID: 17949477
[TBL] [Abstract][Full Text] [Related]
10. Laboratory diagnosis and molecular classification of von Willebrand disease.
Gadisseur A; Hermans C; Berneman Z; Schroyens W; Deckmyn H; Michiels JJ
Acta Haematol; 2009; 121(2-3):71-84. PubMed ID: 19506352
[TBL] [Abstract][Full Text] [Related]
11. Survival of von Willebrand factor released following DDAVP in a type 1 von Willebrand disease cohort: influence of glycosylation, proteolysis and gene mutations.
Millar CM; Riddell AF; Brown SA; Starke R; Mackie I; Bowen DJ; Jenkins PV; van Mourik JA
Thromb Haemost; 2008 May; 99(5):916-24. PubMed ID: 18449422
[TBL] [Abstract][Full Text] [Related]
12. Recessive von Willebrand disease type 2 Normandy: variable expression of mild hemophilia and VWD type 1.
Michiels JJ; Gadisseur A; Vangenegten I; Schroyens W; Berneman Z
Acta Haematol; 2009; 121(2-3):119-27. PubMed ID: 19506358
[TBL] [Abstract][Full Text] [Related]
13. A new candidate mutation, G1629R, in a patient with type 2A von Willebrand's disease: basic mechanisms and clinical implications.
Hilbert L; Federici AB; Baronciani L; Dallagiovanna S; Mazurier C
Haematologica; 2004 Sep; 89(9):1128-33. PubMed ID: 15377475
[TBL] [Abstract][Full Text] [Related]
14. Laboratory and molecular characteristics of recessive von Willebrand disease type 2C (2A subtype IIC) of variable severity due to homozygous or double heterozygous mutations in the D1 and D2 domains.
Michiels JJ; Gadisseur A; van der Planken M; Schroyens W; Berneman Z
Acta Haematol; 2009; 121(2-3):111-8. PubMed ID: 19506357
[TBL] [Abstract][Full Text] [Related]
15. Altered von Willebrand factor subunit proteolysis and multimer processing associated with the Cys2362Phe mutation in the B2 domain.
Casonato A; De Marco L; Gallinaro L; Sztukowska M; Mazzuccato M; Battiston M; Pagnan A; Ruggeri ZM
Thromb Haemost; 2007 Apr; 97(4):527-33. PubMed ID: 17393013
[TBL] [Abstract][Full Text] [Related]
16. Insights into von Willebrand factor proteolysis: clinical implications.
Bowen DJ; Collins PW
Br J Haematol; 2006 Jun; 133(5):457-67. PubMed ID: 16681634
[TBL] [Abstract][Full Text] [Related]
17. Autosomal dominant von Willebrand disease type 2M.
Hermans C; Batlle J
Acta Haematol; 2009; 121(2-3):139-44. PubMed ID: 19506360
[TBL] [Abstract][Full Text] [Related]
18. Dominant von Willebrand disease type 2M and 2U are variable expressions of one distinct disease entity caused by loss-of-function mutations in the A1 domain of the von Willebrand factor gene.
Gadisseur A; van der Planken M; Schroyens W; Berneman Z; Michiels JJ
Acta Haematol; 2009; 121(2-3):145-53. PubMed ID: 19506361
[TBL] [Abstract][Full Text] [Related]
19. The association between the L1565 variant of von Willebrand factor and susceptibility to proteolysis by ADAMTS13.
Davies JA; Bowen DJ
Haematologica; 2007 Feb; 92(2):240-3. PubMed ID: 17296575
[TBL] [Abstract][Full Text] [Related]
20. Genetics of type 1 von Willebrand disease.
Goodeve A
Curr Opin Hematol; 2007 Sep; 14(5):444-9. PubMed ID: 17934350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
